Clinical profile and outcomes of Non-Hodgkin's lymphoma in children: A report from a tertiary care hospital from India

We report a 25-year-old lady presenting to the outpatient department of a tertiary care hospital with spinal cord compression. Initially we had a diagnostic difficulty, as its presentation was perplexing. Finally we pointed towards the diagnosis of non- Hodgkin’s lymphoma and proved it. This article carries a message for the clinicians as clinical fallacies were noticed towards pointing this diagnosis. We have clearly explained the shortcomings in evaluating a case making a diagnosis towards non- Hodgkin’s lymphoma and spinal cord compression, as many situations in the setting were simulating and overlapping.

Download Full-text

Delays in the Cancer Pathway from Symptom Onset to Initiation of Treatment – A Retrospective Study in Patients with Non-Hodgkin’s Lymphoma.

Blood ◽

10.1182/blood.v108.11.347.347 ◽

2006 ◽

Vol 108 (11) ◽

pp. 347-347 ◽

Cited By ~ 2

Author(s):

Reem Nassur ◽

Joy Mangel ◽

Ian Chin-Yee

Keyword(s):

Waiting Time ◽

Symptom Onset ◽

Hodgkin’S Lymphoma ◽

Tertiary Care ◽

Significant Proportion ◽

Pathological Diagnosis ◽

Hodgkin's Lymphoma ◽

Patient Anxiety ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Abstract Background: Cancer patients may experience significant delays along the clinical pathway from the onset of symptoms to initiation of treatment. Few studies have examined the nature or the extent of these delays in patients with non-Hodgkin’s lymphoma (NHL). Method: London Regional Cancer Program (LRCP) is a tertiary care centre with a referral base of 1.5 million people in Southwestern Ontario. In this study, the charts of all patients with newly diagnosed NHL that were seen at the LRCP between Jan 1 – Dec 31, 2004 were reviewed retrospectively in order to measure and document the amount of time spent at each stage of the cancer pathway. Key time intervals from symptom onset to initiation of treatment were recorded. Associations between the waiting times and clinical/sociodemographic factors were also explored. Results: The charts of 116 patients were reviewed. The median overall waiting time from symptom onset to the initiation of treatment was 137 days. Median waiting time for each interval in the pathway were as follows: from symptom onset to first visit with primary care physician: 17 days; from first visit with physician to surgical consultation: 28 days; from surgical consult to the definitive biopsy: 13 days; from definitive biopsy to pathological diagnosis: 10 days; from pathological diagnosis to hematology referral: −5 days; from hematology referral to hematology consultation: 8 days; from hematology consult to completion of staging: 8 days; and from final staging to initiation of treatment: 5 days. The time from symptom onset to treatment initiation varied somewhat by clinical factors such as gender, age, and presence of B-symptoms. Patients with B-symptoms experienced shorter delays (119 d) than patients without B-symptoms (154 d). Male patients had shorter pathway times (113 d) compared to female patients (138 d). Patients at the extremes of age (age 20–29 & age >80) tended to have shorter delays than patients between the ages of 30–79 (ages 20–29: 60d, age >80: 85d, ages 30–79:137 d). Whether patients were referred from London vs. from another municipality did not appear to influence delays (137 d). Conclusions: NHL patients are experiencing significant delays in the assessment and treatment of their cancer. Most prior studies have focused primarily on delays from the point of referral to a cancer specialist to initiation of treatment. The results from our study suggest that a significant proportion of the patient’s clinical path is being spent at the prediagnosis phase (from the time of first physician visit until pathological diagnosis, 57 days) as opposed to from the time of diagnosis until the initiation of treatment (18 days). Efforts to reduce delays at both the pre- and post-diagnosis phases of the patient path may reduce patient anxiety with subsequent improvements in quality of life. The clinical impact of these delays on patient outcome is uncertain and requires further study.

Download Full-text

Adult Non Hodgkin's Lymphoma Patients: Experience from a Tertiary Care Cancer Centre in North East India

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2015.16.7.2879 ◽

2015 ◽

Vol 16 (7) ◽

pp. 2879-2881 ◽

Cited By ~ 1

Author(s):

Munlima Hazarika ◽

Asif Iqbal ◽

Manigreeva Krishnatreya ◽

Jagannath Dev Sharma ◽

Chidananda Bhuyan ◽

...

Keyword(s):

Hodgkin’S Lymphoma ◽

Tertiary Care ◽

Hodgkin's Lymphoma ◽

Cancer Centre ◽

North East India ◽

North East ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Patients Experience

Download Full-text

Primary Sinonasal non-hodgkin's lymphoma: Our experiences at a tertiary care teaching hospital of Eastern India

Medical Journal of Babylon ◽

10.4103/mjbl.mjbl_39_20 ◽

2021 ◽

Vol 18 (2) ◽

pp. 69

Author(s):

SantoshKumar Swain ◽

SoumyaSurath Panda

Keyword(s):

Teaching Hospital ◽

Hodgkin’S Lymphoma ◽

Tertiary Care ◽

Hodgkin's Lymphoma ◽

Eastern India ◽

Tertiary Care Teaching Hospital ◽

Care Teaching ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

B cell non-Hodgkin’s lymphoma: experience from a tertiary care cancer center

Annals of Hematology ◽

10.1007/s00277-012-1491-5 ◽

2012 ◽

Vol 91 (10) ◽

pp. 1603-1611 ◽

Cited By ~ 12

Author(s):

Gaurav Prakash ◽

Atul Sharma ◽

Vinod Raina ◽

Lalit Kumar ◽

M. C. Sharma ◽

...

Keyword(s):

B Cell ◽

Hodgkin’S Lymphoma ◽

Tertiary Care ◽

Hodgkin's Lymphoma ◽

Cancer Center ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma

Download Full-text

Histomorphological Features of Neoplastic and Non-Neoplastic Lymph Node Lesions in a Tertiary Care Hospital in South India

Journal of Evidence Based Medicine and Healthcare ◽

10.18410/jebmh/2021/342 ◽

2021 ◽

Vol 8 (22) ◽

pp. 1814-1819

Author(s):

Lali Krishnan Rajan ◽

Priya Venugopaladas Saraswathy ◽

Sheela Kizhuvelil Mohammed Ali ◽

Deepthi Raj Madambithara Lekshmi

Keyword(s):

Lymph Node ◽

Hodgkin’S Lymphoma ◽

Lymphoid Hyperplasia ◽

Hodgkin's Lymphoma ◽

Reactive Lymphoid Hyperplasia ◽

Tuberculous Lymphadenitis ◽

Care Hospital ◽

Non Hodgkin’S Lymphoma ◽

Non Hodgkin's Lymphoma ◽

Neoplastic Lesions

BACKGROUND Lymphadenopathy is a common clinical condition and biopsies are usually undertaken to determine the cause of nodal enlargement, which may be neoplastic or non-neoplastic. The neoplastic disorders are categorized into haematolymphoid malignancies and metastasis, while the causes of non-neoplastic lymphadenopathy are diverse. This study was undertaken to determine the histopathological spectrum in lymph node biopsies. METHODS This was a descriptive study of 357 cases of histologically diagnosed peripheral lymph node biopsies in the Department of Pathology, Govt. Medical College, Thiruvananthapuram, Kerala, S. India conducted from January 2019 to December 2019. Treated cases of malignancies were excluded. RESULTS The non-neoplastic lesions were more common accounting for 67.2 % (240 cases) which included 40.3 % (144 cases) of non-specific reactive lymphoid hyperplasia, 3.9 % (14 cases) of other specific lymphoid hyperplasia, 16.2 % (58 cases) of tuberculous lymphadenitis, 6.7 % (24 cases) of other granulomatous lesions. Neoplastic lesions accounted for 32.8 % (117 cases) and included 16.2 % (58 cases) of non-Hodgkin’s lymphoma, 3.9 % (14 cases) of Hodgkin’s lymphoma and 12.6 % (45 cases) of metastatic lesions. CONCLUSIONS Lymph node biopsy plays an important role in establishing the cause of lymphadenopathy. Among the biopsied nodes, reactive follicular hyperplasia was the most common (40.3 %) followed by Non-Hodgkin’s lymphoma and tuberculous lymphadenitis (16.2 % each) and metastasis (12.6 %). KEYWORDS Lymphadenopathy, Lymph Node, Metastasis, Non-Hodgkin’s Lymphoma, Reactive Lymphoid Hyperplasia, Tuberculosis

Download Full-text